AUTHORS
Narendranath Epperla, MD, MS, FACP, Kim Saverno, PhD, RPh2, Irina Pivneva, PhD3, Sakshi Sethi4, Lucila Sackmann, PhD5, Andrea Zaffalon6, Julie Wu7, Loren Ormenaj8, Mariana Bastos-Oreiro, MD, PhD9
AFFILIATIONS
1 Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States
2 Incyte Corporation, Wilmington, Delaware, United States
3 Analysis Group Inc, Montreal, Quebec, Canada
4 Analysis Group Inc., New York, New York, United States
5 Incyte Corporation, Wilmington, Delaware, United States
6 Incyte Corporation, Wilmington, Delaware, United States
7 Incyte Corporation, Wilmington, Delaware, United States
8 Analysis Group Inc., New York, New York, United States
9 Gregorio Marañón Hospital, Health Research Institute of Hospital General Universitario Gregorio Marañón, Madrid, Spain
ABSTRACT
Introduction: The treatment landscape for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) has expanded with the availability of CD19-directed therapies, including tafasitamab and chimeric antigen receptor T-cell (CAR-T) therapy. However, prior exposure to anti-CD19 therapy has been hypothesized to compromise the efficacy of subsequent CAR-T treatment due to potential impacts on CD19 antigen availability. Although several studies have demonstrated retention of CD19 expression following tafasitamab exposure, evidence on the effectiveness and safety of sequential CAR-T use after tafasitamab remains limited. We conducted a global, real-world study to evaluate the effectiveness and safety of CAR-T after tafasitamab in patients with R/R DLBCL. Results from the overall study population were previously presented at the 2026 European Hematology Association Congress (PS2089). Here, we report the results for patients treated in the United States (US).
Methods: A retrospective, panel-based chart review collected data for adults in the US and European Union with R/R DLBCL who received tafasitamab and subsequent CAR-T (index date). Patients had to have received tafasitamab (± lenalidomide) in the second-line (2L) or 3L setting or as bridging therapy for CAR-T, followed by 2L, 3L, or 4L CAR-T therapy. Patients had to have ≥6 months of follow-up post CAR-T, except in the event of death, and were followed until the earlier of either start of new anticancer therapy after CAR-T, end of data availability, or death. Outcomes included overall response rate (ORR) to CAR-T (proportion of patients with physician-assessed complete/partial response [CR/PR]), proportion of patients with cytokine release syndrome (CRS) ≤6 weeks, and immune effector cell–associated neurotoxicity syndrome (ICANS) ≤3 months after CAR-T. CRS and ICANS were reported by the participating physician on the study case report form, without application of standardized grading. Outcomes were reported overall; ORR, CR, and PR also reported by line of CAR-T.
Results: Of the 338 patients in this study, 168 (49.7%) were from the US and were included in this analysis. A total of 73 physicians, of whom 39.7% were from academic medical centers, abstracted data for US patients. Among these patients, 65.5% were male, 66.1% were White, and 86.9% were non-Hispanic or Latino. Most patients (78.0%) received CAR-T at the participating physician’s practice. At the time of CAR-T administration, median (interquartile range [IQR]) age was 62.1 (55.3, 67.6) years and 48.2% had revised International Prognostic Index score of ≥3. Additionally, most patients had Ann Arbor stage III (38.7%) or IV (33.9%), 26.8% had bulky disease, and 21.4% had extranodal involvement. The median (IQR) duration of tafasitamab treatment among US patients was 4.1 (2.5, 5.7) months.
Most US patients (81.5%) received tafasitamab in the 2L setting, similar to the overall population. Among these patients, 10.2% also received tafasitamab as bridging treatment before CAR-T. Median (IQR) time from last tafasitamab dose until CAR-T administration was 1.3 (0.7, 2.6) months. CAR-T therapies administered were axicabtagene ciloleucel (57.1%), lisocabtagene maraleucel (28.6%), or tisagenlecleucel (14.3%). Median (IQR) follow-up post CAR-T was 8.0 (6.2, 12.4) months.
Among US patients (n=168), ORR to CAR-T was 83.9% (CR, 62.5%; PR, 21.4%). In patients receiving CAR-T in 2L (n=16), ORR was 100.0% (CR, 68.8%; PR, 31.3%); in 3L (n=133), 83.5% (CR, 63.9%; PR, 19.5%); and in 4L (n=19), 73.7% (CR, 47.4%; PR, 26.3%). CRS occurred in 26.2% of patients, with 1.8% experiencing severe (grade ≥3) CRS, and ICANS occurred in 8.9% of patients, with no severe ICANS reported.
In the overall population, ORR to CAR-T was 81.1%, while CRS and ICANS occurred in 30.8% and 15.4% of patients, respectively, consistent with outcomes for US patients.
Conclusions: Findings from this US-based analysis demonstrated favorable effectiveness and safety outcomes following CAR-T therapy in patients with R/R DLBCL who had previously received tafasitamab. Results for US patients closely reflect the findings for the overall study population and are particularly relevant given the recent phase 3 evidence for tafasitamab in the 1L DLBCL setting. Although these findings should be interpreted in the context of an observational cohort, data support the sequential use of CAR-T after tafasitamab as a viable treatment sequencing strategy in clinical practice.
DISCLOSURES
Narendranath Epperla, MD, MS, FACP: CRISPR Therapeutics - Research Funding; BeOne - Research Funding; AbbVie - Research Funding; Ipsen - Research Funding; Incyte - Research Funding; ADC Therapeutics - Research Funding; ADC Therapeutics - Research Funding; Eli Lilly - Research Funding; Genetech - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)